Advancing RNA medicines through safer and more effective lipid nanoparticle delivery
Axelyf Strengthens Leadership Team
December 16, 2025 - Axelyf has announced the appointment of Daniel Frímannsson, PhD, as Head of Nucleic Acid Technologies and Biology, and Leslie Williams to the Board of Directors. These appointments significantly strengthen the company’s RNA therapeutics strategy by adding deep technical expertise in nucleic acid delivery and proven executive leadership to support Axelyf’s next phase of growth.
A team of experts, driven by passion and precision
Founded in Hafnarfjörður, Iceland, the Axelyf team leverages decades of expertise in pharmaceutical R&D and its global network of partners and collaborators to specialize in optimizing delivery systems for promising small molecule drugs derived from natural sources.